Tubingen, Germany-based CureVac entered a collaboration research agreement with Yale University to focus on lung therapies.
Despite concerns about potential competition from recently approved and available European biosimilars to Humira, AbbVie was able to stave off some of the losses expected during Q2 2019.
French drugs and healthcare group Sanofi signed a rights deal with Roche for Tamiflu in the United States.
A collaboration and license deal was inked with Gilead Sciences Inc. to develop and market a long-acting injectable HIV therapy using Durect Corp.’s SABER technology.
Germany’s Bayer signed a deal to sell the company’s Dr. Scholl’s footcare brand to U.S. private investment firm Yellow Wood Partners for $585 million.
In a deal-making morning for South San Francisco-based Genentech, the Roche subsidiary struck three separate transactions with small companies to boost drug development.
Illinois-based AbbVie announced that the company will acquire Ireland-based Allergan for $63 billion in a cash and stock deal.
GlaxoSmithKline offered concessions to address EU antitrust concerns over the planned joint venture with Pfizer’s consumer health business, the European Commission said.
Vancouver-based AbCellera and Gilead Sciences forged a collaborative agreement to discover and develop ultra-rare antibodies that can be used in the treatment of a number of infectious diseases.
Stada said on Friday the private equity-backed company would buy six consumer healthcare products from British GlaxoSmithKline to bolster the generic drugmaker’s presence in Europe.